| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | SOPHIRIS BIO INC | 200,000 | 566,000 | 0.30% | ||
| 2 | INNOCOLL HLDGS PLC | 2,103,173 | 2,356,000 | 1.24% | ||
| 3 | HISTOGENICS CORP | 2,077,040 | 3,593,000 | 1.90% | ||
| 4 | Mirna Therapeutics, Inc. | 2,974,812 | 6,515,000 | 3.44% | ||
| 5 | AURIS MED HLDG AG | 7,818,175 | 7,193,000 | 3.79% | ||
| 6 | Natera, Inc. | 1,550,280 | 13,751,000 | 7.25% | ||
| 7 | VERSARTIS INC | 1,563,260 | 33,376,000 | 17.60% | ||
| 8 | SPARK THERAPEUTICS INCORPORATED | 699,430 | 37,308,000 | 19.68% | ||
| 9 | ObsEva SA | 3,749,623 | 39,034,000 | 20.59% | ||
| 10 | ACLARIS THERAPEUTICS INC COM | 1,539,480 | 45,907,000 | 24.21% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001144204-17-019868, filed 2017.04.10).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
